In women who had ER-positive disease (n = 10,645), tamoxifen significantly reduced the long-term risk for breast cancer recurrence and death. The relative risk (RR) for recurrence was nearly halved during tamoxifen treatment (0.53 during years 0 to 4). It was also significantly reduced, by...
There are various treatments for estrogen-positive breast cancer, mainly hormone therapy and molecular-targeted drugs. Acquiring resistance to these drugs is a major clinical problem. Additionally, little is known about the effect of drug resistance on the DNA repair mechanism. Poly ADP ribose ...
at a rational and effective treatment, some clinical trials recently have demonstrated that compared to endocrine therapy alone, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy can significantly improve the prognosis of ER-positive, HER2-negative advanced breast cancer....
For women with HER2-positive breast cancers, the targeted drugtrastuzumab(Herceptin) has been shown to dramatically reduce the risk of the cancer coming back. It‘s standard treatment to give this medication along withchemotherapyafter surgery to people with breast cancer that’s spread to other ar...
and patients are routinely treated with drugs like tamoxifen or aromatase inhibitors that block estrogen stimulation of thecancercells. However, these drugs almost always stop working in metastatic ER-positive breast cancers due to the development of drug resistance. In 25 to 30 percent of such pati...
Optimization of Neoadjuvant Treatment: Triple-Negative Breast Cancer Neoadjuvant chemotherapy stands as the cornerstone in the medical management of TNBC exceeding 2 cm or displaying positive lymph nodes. However, primary surgery holds a preference in specific scenarios. Definitive pathological staging prove...
A regulatory assessment of elacestrant for the treatment of ER-positive, HER2-negative advanced or metastatic breast cancer is currently underway in the ... SM Hoy - Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Arti...
[1] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer [2] https://www.menarini.com/en-us/news/news-detail/st...
Targeting ERα has been a cornerstone in the treatment of ERα-positive breast cancer.11 These therapies encompass selective estrogen receptor modulators (SERMs), such as tamoxifen, which competitively inhibit estrogen binding to ERα,12 and selective estrogen receptor degraders (SERDs), such as ...
not. A University of Colorado Cancer Center study recently published in the journalBreast Cancer Research and Treatmentreports the development of human-derived estrogen-positive (ER+) breast cancer models that retain their heterogeneity, allowing researchers to more accurately test drugs for this disease...